Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream

Exclusion Criteria

• •Pregnancy or lactation.
• •Spontaneously improving or rapidly deteriorating atopic dermatitis.
• •Presence of atopic dermatitis on only hands and/or feet.
• •Any skin disease other than atopic dermatitis that might interfere with clinical assessment or put patient at risk.
• •Active allergic contact dermatitis or other non-atopic forms of atopic dermatitis.
• •Other concommitant serious illness or medical condition, virus or renal insufficiency, or clinically significant abnormality that could put patient at risk during the study.
• •History of neurological/psychiatric disorders including psychotic disorders, dementia or any other reason that would interfere with the patient's participation.
• •Systemic immunomodulatory therapies for other conditions within 4 weeks prior to the baseline visit.
• •Any phototherapy, photochemotherapy or systemic atopic dermatitis therapy within 2 weeks of the baseline visit.
• •Prolonged exposure to natural or artificial sources of UV within 4 weeks prior to baseline visit or intention to have such exposure during the study.
• •Topical atopic dermatitis therapies (including corticosteroids and calcineurins) in the areas to be treated within 2 weeks prior to baseline.
• •Alcohol abuse in the last 2 years.
• •Allergic history to any of the non-medical ingredients of the study cream.
• •Treatment with an investigational drug within one month of Day 0 or current participation in another clinical trial.